LNSR

Company Overview — What Does LENSAR, Inc. Do?

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida. LENSAR, Inc. (LNSR) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Nicholas T. Curtis and employs approximately 110 people. With a market capitalization of $72M, LNSR is one of the notable companies in the Healthcare sector.

LENSAR, Inc. (LNSR) Stock Rating — Reduce (April 2026)

As of April 2026, LENSAR, Inc. receives a Reduce rating with a composite score of 30.3/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.LNSR ranks #3,865 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, LENSAR, Inc. ranks #656 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

LNSR Stock Price and 52-Week Range

LENSAR, Inc. (LNSR) currently trades at $5.70. The stock gained $0.24 (4.4%) in the most recent trading session. The 52-week high for LNSR is $16.94, which means the stock is currently trading -66.4% from its annual peak. The 52-week low is $6.55, putting the stock -13.0% above its annual trough. Recent trading volume was 46K shares, suggesting relatively thin trading activity.

Is LNSR Overvalued or Undervalued? — Valuation Analysis

LENSAR, Inc. (LNSR) carries a value factor score of 15/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-sales ratio is 1.22x, compared to 1.66x for the average Healthcare stock.

At current multiples, LENSAR, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

LENSAR, Inc. Profitability — ROE, Margins, and Quality Score

LENSAR, Inc. (LNSR) earns a quality factor score of 31/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -422.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -48.0% versus the sector average of -33.1%.

On a margin basis, LENSAR, Inc. reports gross margins of 47.3%, compared to 71.5% for the sector. The operating margin is -37.0% (sector: -66.1%). Net profit margin stands at -60.7%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 13.3% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

LNSR Debt, Balance Sheet, and Financial Health

LENSAR, Inc. has a debt-to-equity ratio of 0.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 1.15x, suggesting adequate working capital coverage. Total debt on the balance sheet is $0. Cash and equivalents stand at $8M.

LNSR has a beta of 0.33, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for LENSAR, Inc. is 49/100, reflecting average volatility within the normal range for its sector.

LENSAR, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, LENSAR, Inc. reported revenue of $56M and earnings per share (EPS) of $-2.87. Net income for the quarter was $-34M. Gross margin was 47.3%. Operating income came in at $-21M.

In FY 2025, LENSAR, Inc. reported revenue of $58M and earnings per share (EPS) of $-2.87. Net income for the quarter was $-34M. Gross margin was 46.4%. Revenue grew 9.2% year-over-year compared to FY 2024. Operating income came in at $-25M.

In Q3 2025, LENSAR, Inc. reported revenue of $14M and earnings per share (EPS) of $-0.31. Net income for the quarter was $-4M. Gross margin was 42.2%. Revenue grew 5.7% year-over-year compared to Q3 2024. Operating income came in at $-8M.

In Q2 2025, LENSAR, Inc. reported revenue of $14M and earnings per share (EPS) of $-0.15. Net income for the quarter was $-2M. Gross margin was 50.4%. Revenue grew 10.3% year-over-year compared to Q2 2024. Operating income came in at $-6M.

Over the past 8 quarters, LENSAR, Inc. has demonstrated a growth trajectory, with revenue expanding from $13M to $56M. Investors analyzing LNSR stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

LNSR Dividend Yield and Income Analysis

LENSAR, Inc. (LNSR) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

LNSR Momentum and Technical Analysis Profile

LENSAR, Inc. (LNSR) has a momentum factor score of 18/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 28/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 68/100 reflects moderate short selling activity.

LNSR vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, LENSAR, Inc. (LNSR) ranks #656 out of 838 stocks based on the Blank Capital composite score. This places LNSR in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing LNSR against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full LNSR vs S&P 500 (SPY) comparison to assess how LENSAR, Inc. stacks up against the broader market across all factor dimensions.

LNSR Next Earnings Date

No upcoming earnings date has been announced for LENSAR, Inc. (LNSR) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy LNSR? — Investment Thesis Summary

The quantitative profile for LENSAR, Inc. suggests caution. The quality score of 31/100 flags below-average profitability. The value score of 15/100 indicates premium valuation. Momentum is weak at 18/100, a headwind for near-term performance.

In summary, LENSAR, Inc. (LNSR) earns a Reduce rating with a composite score of 30.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on LNSR stock.

Related Resources for LNSR Investors

Explore more research and tools: LNSR vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare LNSR head-to-head with peers: LNSR vs AZN, LNSR vs SLGL, LNSR vs VMD.